How Much Muscle Do You Lose on Ozempic & Wegovy?

How much muscle do you lose on Ozempic or Wegovy? DXA-based trial data suggests roughly 25-40% of the total weight you lose on semaglutide can be lean mass rather than fat, with some studies landing near 40%. That is a real chunk, but it is not fixed; your protein intake and training largely decide where in that range you land.

This article walks through the actual trial numbers, explains why "lean mass" is not the same as "skeletal muscle," and shows what moves the share up or down.

What percentage of Ozempic weight loss is muscle?

The honest answer is a range, not a single number, and you should be suspicious of anyone who gives you one clean figure. The most-cited estimates come from trials that used DXA (dual-energy X-ray absorptiometry, the scan that separates fat from lean tissue).

In SUSTAIN 8, a 52-week semaglutide trial, participants lost about 3.4 kg of fat and 2.3 kg of lean mass, putting the lean share of total weight lost at roughly 40%. In the STEP 1 DXA analysis, 68 weeks of semaglutide produced about 15% total weight loss, with lean body mass down about 9.7% in absolute terms. The widely repeated "~39-40%" figure for semaglutide is essentially a synthesis of these two trials, and it is a reasonable approximation rather than a precise constant.

There is a crucial nuance the headline number hides. In STEP 1, even though absolute lean mass fell, the proportion of the body that was lean rose by about 3 points. In plain terms: participants became relatively leaner. Absolute lean mass goes down, but the lean-to-fat ratio improves, which is true across nearly all of these trials.

It is also worth noting these were the average results. Trials report means, and individuals scatter widely around that mean depending on their diet and activity. Some participants in any of these studies almost certainly preserved nearly all their muscle, while others lost more than the average, and the difference largely came down to protein and movement. So the "40%" you read about is not your destiny; it is the midpoint of a wide distribution you can position yourself within.

Why "lean mass" overstates muscle loss

When a trial says lean body mass fell, that is not all biceps and quads. Lean mass includes skeletal muscle plus water, organs, and connective tissue. Some of the early lean-mass drop on a GLP-1 is water and glycogen, not contractile muscle. So when you read "40% of weight lost was lean," the share that is true, functional skeletal muscle is meaningfully lower than 40%. This is why we hedge the figure everywhere, and why a body-composition trend matters more than any one scary statistic. To understand the underlying cause, see why GLP-1 drugs cause muscle loss.

Do you lose more muscle on Wegovy or Ozempic?

This question comes up constantly, and the answer surprises people: Ozempic and Wegovy are the same drug. Both are semaglutide, just approved and marketed at different doses (Ozempic for type 2 diabetes, Wegovy for weight management, generally at higher doses). Because the active molecule and the mechanism are identical, there is no reason to expect one brand to spare muscle better than the other at a matched rate of weight loss.

What differs is the dose, and dose drives the rate of loss. Higher doses tend to produce faster, larger weight loss, and faster loss generally means a higher proportion of lean mass shed. So if anything, the muscle-loss question is less about "Ozempic vs Wegovy" and more about how quickly you are losing and what you are doing to defend muscle while it happens. The same logic applies to compounded semaglutide drawn in custom doses, which is its own tracking challenge covered in tracking compounded semaglutide and tirzepatide doses.

How semaglutide compares to tirzepatide

The semaglutide numbers look higher than the tirzepatide (Mounjaro/Zepbound) numbers, and it is worth seeing them side by side. The table below puts the key semaglutide trials (STEP, SUSTAIN) next to the tirzepatide SURMOUNT data.

Trial / drug	Duration	Total weight lost	Lean-mass share of loss	Population
SUSTAIN 8 (semaglutide)	52 wks	~5.7 kg total (fat -3.4, lean -2.3)	~40%	Type 2 diabetes, DXA RCT
STEP 1 DXA analysis (semaglutide)	68 wks	~15% body weight	~39-40% (lean down 9.7% absolute, lean proportion rose ~3 pts)	Adults with obesity, no diabetes
SURMOUNT-1 DXA substudy (tirzepatide)	72 wks	~21.3% body weight	~25% (fat down ~34%, lean down ~11%)	Adults with obesity, DXA substudy

On paper, tirzepatide trials report a lower lean-mass share (~25%) than semaglutide trials (~40%). But read that carefully: tirzepatide participants also lost substantially more total weight, and trial designs, populations, and measurement timing differed. This is suggestive, not a proven head-to-head win. We compare the two more fully in the complete guide to GLP-1 muscle loss.

Strength data adds reassurance. In the real-world SEMALEAN cohort, lean mass dropped about 3 kg early and then stabilized, sarcopenic obesity fell from 49% to 33% over a year, and handgrip strength actually rose by roughly 4 kg. People losing muscle on paper were getting functionally stronger, which is a reminder that the lean-mass number alone does not tell the whole story.

What makes the muscle-loss share higher or lower?

Three factors do most of the work.

Rate of loss. Faster weight loss generally means a higher proportion of lean mass lost. The aggressive appetite suppression that makes GLP-1s effective is also what tips some people into losing weight faster than their muscle can be defended.

Protein intake. This is the big one. GLP-1s cut overall food intake by roughly 16-39% in trials, and protein usually falls with it. A 2025 study found fewer than half of GLP-1 users (about 43%) hit even the 1.2 g/kg per day minimum recommended during weight loss. When protein drops, your body loses both the raw material and the signal to maintain muscle. The targets are spelled out in how much protein to eat on a GLP-1.

Resistance training. A meta-analysis found resistance training offset roughly 93% of the lean-mass loss caused by calorie restriction, versus dieting alone. Without that training stimulus, the muscle-loss share trends toward the high end of the range.

Stack the unfavorable versions of all three (fast loss, low protein, no lifting) and you are aiming at the 40% end. Stack the favorable versions and you push toward mostly-fat loss.

Is losing muscle on semaglutide dangerous?

For most healthy adults, the muscle loss seen in trials is a manageable side effect rather than an emergency, especially given that the lean-to-fat ratio usually improves. You are not turning frail; you are becoming relatively leaner while shedding some lean tissue along the way. The DXA numbers look alarming partly because they include water and glycogen, as noted above.

The picture changes for older adults. Low muscle and strength, the markers of sarcopenia, are linked to falls, functional decline, insulin resistance, and higher mortality, and that risk rises after about age 60. If you are in that group, or if you are losing weight unusually fast on very low protein and no resistance training, the muscle loss is worth taking seriously and worth discussing with your prescriber. The warning signs to watch for are laid out in 7 signs you are losing muscle on a GLP-1. The point is not to scare you off an effective medication; it is to make sure the weight you lose is mostly the weight you want gone.

Can you avoid muscle loss on Ozempic entirely?

Realistically, no, you cannot get to zero. Some lean-mass loss accompanies almost any significant weight loss, and a portion of the early drop is water and glycogen that will come and go regardless. Chasing "zero lean-mass loss" is the wrong target.

The right target is to lose mostly fat and hold most of your muscle. Research suggests that is very achievable: resistance training offset roughly 93% of diet-induced lean-mass loss in one meta-analysis, and adequate protein supports that defense. Hit your protein and lift a few times a week, and you can plausibly turn a 40%-lean-loss trajectory into something far closer to mostly-fat loss. That is the realistic, evidence-based goal, not perfection.

How to know your own number

Here is the part the trial averages cannot give you: your personal muscle-loss share. The published percentages are population means from controlled studies, not a prediction for you. What actually determines your ratio is your own protein and training, and the only way to know which way you are trending is to measure body composition over time rather than trusting the scale, which cannot tell fat from muscle at all. See the method comparison in how to track muscle loss on a GLP-1 and the broader question of fat loss vs muscle loss.

This is the gap Myo is built for. Rather than reporting "you lost 4 lb," it trends your fat mass and lean mass separately against your logged protein and resistance sessions, so you can see whether your personal share is tracking toward the good end of that 25-40% range or the bad one. A trial gives you an average; your own data gives you the answer.

The practical workflow is simple. Pick one body-composition method you can repeat consistently, whether that is a periodic DEXA scan, an InBody reading at the gym, or a smart scale used the same way every morning. Log the lean-mass number over time, log your daily protein, and log your training. Then watch the trend, not any single reading, because day-to-day fluctuations in water and food can swing a lean-mass figure by more than your actual muscle changes in a week. Over six to twelve weeks, the direction of the line tells you whether your share is closer to 25% or closer to 40%, and gives you something concrete to adjust if it is drifting the wrong way.

The bottom line: "how much muscle do you lose on Ozempic" has a population answer (roughly 25-40% of weight lost as lean mass) and a personal answer (whatever your protein and training produce). The first is interesting trivia. The second is the one you can change, and the one worth measuring.

References

• SUSTAIN 8 (Diabetes, Obesity and Metabolism, 2020)
• STEP 1 DXA analysis (Journal of the Endocrine Society)
• SURMOUNT-1 DXA substudy (DOM 2025)
• SEMALEAN real-world cohort (2025)
• Protein intake in GLP-1 users (Johnson et al., 2025)
• Resistance training and lean-mass preservation meta-analysis
• OMA/TOS/ACLM/ASN joint advisory (2025)